Five-year risk of incident pancreatic cancer in patients with type 2 diabetes, with and without tobacco use disorder (Comparison between propensity-score matched groups)

Size/group	Exposure group	Comparison group	# of cases (overall risk) (Exposure group)	# of cases (overall risk) (Comparison group)		HR (95% CI)
	Tobbaco use disorder					
7,666	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	13 (0.18%)	51 (0.67%)		0.23 (0.12–0.42)
6,494	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	22 (0.34%)	41 (0.63%)		0.51 (0.30-0.85)
17,807	GLP-1RA(+)DDP-4i(-)	DPP-4i(+)GLP-1RA(-)	55 (0.31%)	77 (0.43%)	├──	0.65 (0.46-0.92)
10,146	GLP-1RA(+)SGLTi2(-)	SGLT2i(+)GLP-1RA(-)	36 (0.36%)	77 (0.76%)		0.43 (0.29–0.64)
15,208	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	49 (0.32%)	72 (0.47%)	⊢	0.62 (0.43-0.89)
9,387	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	35 (0.37%)	61 (0.65%)	⊢	0.53 (0.35–0.80)
	No tobbaco use disorder					
44,067	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	88 (0.20%)	205 (0.47%)	— ■	0.39 (0.30–0.50)
27,663	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	90 (0.33%)	117 (0.42%)	⊢ ■	0.73 (0.56–0.96)
75,129	GLP-1RA(+)DDP-4i(-)	DPP-4i(+)GLP-1RA(-)	243 (0.32%)	266 (0.35%)	⊢ ■	0.83 (0.70-0.99)
40,857	GLP-1RA(+)SGLTi2(-)	SGLT2i(+)GLP-1RA(-)	153 (0.37%)	178 (0.44%)	⊢ ■	0.79 (0.64–0.98)
66,107	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	195 (0.30%)	267 (0.40%)	⊢■-	0.68 (0.56-0.81)
44,415	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	189 (0.43%)	178 (0.40%)	0.30 0.40 0.60 0.80 2.0 Hazard Ratio (HR)	0.99 (0.81–1.22) 3.00